Other Guidelines | Page 55 | European Cystic Fibrosis Society (ECFS)

CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation

Ebselen attenuates tobramycin-induced ototoxicity in mice

Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis

Lavage lipidomics signatures in children with cystic fibrosis and protracted bacterial bronchitis

“Mild” CFTR genetic variants might be associated with a lower than expected probability of developing CF

Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA

Females with Cystic Fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males

Caring for gender diverse youth with cystic fibrosis

Prevalence of unmet palliative care needs in adults with cystic fibrosis

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

first
previous
…
51
52
53
54
55
56
57
58
59
…
next
last